OBJECTIVE: To evaluate the impact of measures of intraocular pressure (IOP) control on progression of visual field (VF) loss during long-term treatment for open-angle glaucoma (OAG). DESIGN: Longitudinal, randomized clinical trial. PARTICIPANTS: We included 607 participants with newly diagnosed OAG. METHODS: Study participants were randomly assigned to initial treatment with medications or trabeculectomy, and underwent examination at 6-month intervals. Standardized testing included Goldmann applanation tonometry and Humphrey 24-2 full threshold VFs. Summary measures of IOP control during follow-up included the maximum, mean, standard deviation (SD), range, proportion less than 16, 18, 20, or 22 mmHg, and whether all IOP values were less than each of these 4 cutpoints. Predictive models for VF outcomes were based on the mean deviation (MD) from VF testing, and were adjusted for age, gender, race, baseline VF loss, treatment, and time. Each summary IOP measure was included as a cumulative, time-dependent variable, and its association with subsequent VF loss was assessed from 3 to 9 years postrandomization. Both linear mixed models, to detect shifts in MD levels, and logistic models, to detect elevated odds of substantial worsening (≥3 dB), were used. MAIN OUTCOME MEASURES: We measured the MD from Humphrey 24-2 full threshold VF tests. RESULTS: The effect of the summary IOP measures differed between the medicine and surgery groups in models that addressed the continuous MD outcome. After adjustment for baseline risk factors, in the medicine group larger values of 3 IOP control measures-maximum IOP (P = 0.0003), SD of IOP (P = 0.0056), and range of IOP (P<0.0001)-were significantly associated with lower (worse) MD over the 3- to 9-year period. No IOP summary measure was significantly associated with MD over time in the surgery group. The same 3 IOP summary measures were also significantly associated with substantial worsening of MD; however, the effects were similar in both treatment groups. In models predicting inadequate IOP control, consistently significant predictors of higher maximum, SD, and range of IOP included black race, higher baseline IOP, and clinical center. CONCLUSIONS: These results support considering more aggressive treatment when undue elevation or variation in IOP measures is observed.
RCT Entities:
OBJECTIVE: To evaluate the impact of measures of intraocular pressure (IOP) control on progression of visual field (VF) loss during long-term treatment for open-angle glaucoma (OAG). DESIGN: Longitudinal, randomized clinical trial. PARTICIPANTS: We included 607 participants with newly diagnosed OAG. METHODS: Study participants were randomly assigned to initial treatment with medications or trabeculectomy, and underwent examination at 6-month intervals. Standardized testing included Goldmann applanation tonometry and Humphrey 24-2 full threshold VFs. Summary measures of IOP control during follow-up included the maximum, mean, standard deviation (SD), range, proportion less than 16, 18, 20, or 22 mmHg, and whether all IOP values were less than each of these 4 cutpoints. Predictive models for VF outcomes were based on the mean deviation (MD) from VF testing, and were adjusted for age, gender, race, baseline VF loss, treatment, and time. Each summary IOP measure was included as a cumulative, time-dependent variable, and its association with subsequent VF loss was assessed from 3 to 9 years postrandomization. Both linear mixed models, to detect shifts in MD levels, and logistic models, to detect elevated odds of substantial worsening (≥3 dB), were used. MAIN OUTCOME MEASURES: We measured the MD from Humphrey 24-2 full threshold VF tests. RESULTS: The effect of the summary IOP measures differed between the medicine and surgery groups in models that addressed the continuous MD outcome. After adjustment for baseline risk factors, in the medicine group larger values of 3 IOP control measures-maximum IOP (P = 0.0003), SD of IOP (P = 0.0056), and range of IOP (P<0.0001)-were significantly associated with lower (worse) MD over the 3- to 9-year period. No IOP summary measure was significantly associated with MD over time in the surgery group. The same 3 IOP summary measures were also significantly associated with substantial worsening of MD; however, the effects were similar in both treatment groups. In models predicting inadequate IOP control, consistently significant predictors of higher maximum, SD, and range of IOP included black race, higher baseline IOP, and clinical center. CONCLUSIONS: These results support considering more aggressive treatment when undue elevation or variation in IOP measures is observed.
Authors: David S Friedman; Roger C W Wolfs; Benita J O'Colmain; Barbara E Klein; Hugh R Taylor; Shelia West; M Cristina Leske; Paul Mitchell; Nathan Congdon; John Kempen Journal: Arch Ophthalmol Date: 2004-04
Authors: Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2002-06
Authors: Kouros Nouri-Mahdavi; Douglas Hoffman; Anne L Coleman; Gang Liu; Gang Li; Douglas Gaasterland; Joseph Caprioli Journal: Ophthalmology Date: 2004-09 Impact factor: 12.079
Authors: Brenda W Gillespie; David C Musch; Kenneth E Guire; Richard P Mills; Paul R Lichter; Nancy K Janz; Patricia A Wren Journal: Invest Ophthalmol Vis Sci Date: 2003-06 Impact factor: 4.799
Authors: Kaweh Mansouri; Felipe A Medeiros; Nicholas Marchase; Andrew J Tatham; Daniel Auerbach; Robert N Weinreb Journal: Ophthalmology Date: 2013-09-08 Impact factor: 12.079
Authors: Hugh J Morris; Junhua Tang; Benjamin Cruz Perez; Xueliang Pan; Richard T Hart; Paul A Weber; Jun Liu Journal: Invest Ophthalmol Vis Sci Date: 2013-11-01 Impact factor: 4.799
Authors: Keyton Clayson; Xueliang Pan; Elias Pavlatos; Ryan Short; Hugh Morris; Richard T Hart; Jun Liu Journal: Exp Eye Res Date: 2017-08-30 Impact factor: 3.467
Authors: Quang H Nguyen; Matthew G McMenemy; Tony Realini; Jess T Whitson; Stephen M Goode Journal: J Ocul Pharmacol Ther Date: 2013-02-20 Impact factor: 2.671